Global Pulmonary Arterial Hypertension Drugs Market Size, Share, Growth, Global Trends, Industry Analysis and Forecast to 2027

Price: 3995/- USD | Published Date: July 29, 2021 |

The global pulmonary arterial hypertension drugs market size is projected to grow at a significant CAGR during the forecast period 2021 to 2027. The increasing incidence of cardiovascular and pulmonary disorders and the growing geriatric population are some major factors driving the market growth. The changing lifestyle such as increasing consumption of alcohol, low physical activity, and unhealthy diet is expected to increase e the risk of high blood pressure and hypertension, which is expected to fuel the market growth over the forecast period.

Market Segment Insights:

The global pulmonary arterial hypertension drugs market is segmented into drug class, route of administration, distribution channel, and geography. On the basis of drug class, the market is further segmented into prostacyclin & prostacyclin analogs, SGC stimulators, ERA, PDE-5, and others. The prostacyclin & prostacyclin analogs segment dominated the global market in 2020 and accounted to hold the largest market share of around half of the market. The segment growth is attributed to the increased demand for the drug for the treatment. On the other hand, the SGC stimulators segment is expected to grow at the fastest growth rate over the forecast period.

Pulmonary Arterial Hypertension Drugs Market

To know more about the report, request sample papers

The pulmonary arterial hypertension drugs comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2021 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market, and expert opinion obtained from interviews with industry executives and experts from prominent companies.

Global pulmonary arterial hypertension drugs market size and forecast were obtained by using “Bottom-up” and “Top-down” approaches. Extensive secondary research was conducted to understand the market insights and trends, followed by primary interviews to further validate the information sourced. The report provides both, qualitative and quantitative analyses of the market, the competitive landscape, and the preferred development strategies of key players which help to formulate competitive market strategies and make informed decisions.

The pulmonary arterial hypertension drugs market research report presents the analysis of each segment from 2018 to 2027 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

  • 2018-19 – Historical Year
  • 2020 – Base Year
  • 2021-2027 – Forecast Period

Global Pulmonary Arterial Hypertension Drugs Market Segmentation:

By Drug Class:

  • Prostacyclin and Prostacyclin Analogs
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Endothelin Receptor Antagonist (ERA)
  • Phosphodiesterase 5 (PDE-5)
  • Others

By Route of Administration:

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Geographic Coverage:

Geographically, North America dominated the global pulmonary arterial hypertension drugs market in 2020 and accounted to hold the largest revenue share of over half of the market. The increasing diagnosis rate, rising awareness, and government initiative are some major factors contributing to the market growth in the region. Furthermore, the well-structured healthcare infrastructure and high awareness is further expected to fuel the market in North America. In contrast, the Asia Pacific is expected to grow at the fastest growth rate over the forecast period due to the increasing investment in healthcare infrastructure and the growing geriatric population.

Market Competition Assessment:

Some of the major players operating in the global pulmonary arterial hypertension drugs market are Johnson & Johnson Services, Inc., United Therapeutics Corporation, Pfizer, Inc., Acceleron Pharma, Inc., and Gilead Sciences, Inc. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

List of Key Companies:

  • Johnson & Johnson Services, Inc.
  • United Therapeutics Corporation
  • Pfizer, Inc.
  • Acceleron Pharma, Inc.
  • Gilead Sciences, Inc.
  • Bayer AG
  • GlaxoSmithKline Plc.
  • Arena Pharmaceuticals Inc.
  • Merck KGaA
  • Novartis International AG

Key Questions Answered by Pulmonary Arterial Hypertension Drugs Market Report

  • Global pulmonary arterial hypertension drugs market forecasts from 2021-2027
  • Regional pulmonary arterial hypertension drugs market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
  • Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
  • Pulmonary arterial hypertension drugs submarket forecasts from 2021-2027 covering the market by drug class, by route of administration, by distribution channel, and geography
  • Various industry models such as SWOT analysis, Value Chain Analysis pertaining to pulmonary arterial hypertension drugs market
  • Analysis of the key factors driving and restraining the growth of the global, regional and country-level pulmonary arterial hypertension drugs markets from 2021-2027
  • Competitive Landscape and market positioning of top 10 players operating in the pulmonary arterial hypertension drugs market
Table of Content:

1. Preface


1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.4. Assumptions

 

2. Executive Summary


2.1. Global Pulmonary Arterial Hypertension Drugs Market Portraiture
2.2. Global Pulmonary Arterial Hypertension Drugs Market, by Drug Class, 2020 (USD Mn)
2.3. Global Pulmonary Arterial Hypertension Drugs Market, by Route of Administration, 2020 (USD Mn)
2.4. Global Pulmonary Arterial Hypertension Drugs Market, by Distribution Channel, 2020 (USD Mn)
2.5. Global Pulmonary Arterial Hypertension Drugs Market, by Geography, 2020 (USD Mn)

 

3. Global Pulmonary Arterial Hypertension Drugs Market Analysis


3.1. Pulmonary Arterial Hypertension Drugs Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition
3.5. Competitive Analysis
3.6. COVID-19 Impact Analysis

 

4. Global Pulmonary Arterial Hypertension Drugs Market By Drug Class, 2018 – 2027 (USD Mn)


4.1. Overview
4.2. Prostacyclin and Prostacyclin Analogs
4.3. Soluble Guanylate Cyclase (SGC) Stimulators
4.4. Endothelin Receptor Antagonist (ERA)
4.5. Phosphodiesterase 5 (PDE-5)
4.6. Others

 

5. Global Pulmonary Arterial Hypertension Drugs Market By Route of Administration, 2018 – 2027 (USD Mn)


5.1. Overview
5.2. Oral
5.3. Inhaled
5.4. Intravenous
5.5. Subcutaneous

 

6. Global Pulmonary Arterial Hypertension Drugs Market By Distribution Channel, 2018 – 2027 (USD Mn)


6.1. Overview
6.2. Hospital Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies

 

7. North America Pulmonary Arterial Hypertension Drugs Market Analysis and Forecast, 2018 – 2027 (USD Mn)


7.1.1. Overview
7.1.2. North America Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
7.1.3. North America Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
7.1.4. North America Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
7.1.5. North America Pulmonary Arterial Hypertension Drugs Market by Country (2018-2027 USD Mn)
7.1.5.1. U.S.
7.1.5.1.1. U.S. Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
7.1.5.1.2. U.S. Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
7.1.5.1.3. U.S. Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
7.1.5.2. Canada
7.1.5.2.1. Canada Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
7.1.5.2.2. Canada Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
7.1.5.2.3. Canada Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)

 

8. Europe Pulmonary Arterial Hypertension Drugs Market Analysis and Forecast, 2018 – 2027 (USD Mn)


8.1.1. Overview
8.1.2. Europe Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
8.1.3. Europe Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
8.1.4. Europe Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
8.1.5. Europe Pulmonary Arterial Hypertension Drugs Market by Country (2018-2027 USD Mn)
8.1.5.1. Germany
8.1.5.1.1. Germany Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
8.1.5.1.2. Germany Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
8.1.5.1.3. Germany Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
8.1.5.2. U.K.
8.1.5.2.1. U.K. Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
8.1.5.2.2. U.K. Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
8.1.5.2.3. U.K. Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
8.1.5.3. France
8.1.5.3.1. France Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
8.1.5.3.2. France Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
8.1.5.3.3. France Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
8.1.5.4. Italy
8.1.5.4.1. Italy Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
8.1.5.4.2. Italy Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
8.1.5.4.3. Italy Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
8.1.5.5. Rest of Europe
8.1.5.5.1. Rest of Europe Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
8.1.5.5.2. Rest of Europe Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
8.1.5.5.3. Rest of Europe Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)

 

9. Asia Pacific Pulmonary Arterial Hypertension Drugs Market Analysis and Forecast, 2018 – 2027 (USD Mn)


9.1.1. Overview
9.1.2. Asia Pacific Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
9.1.3. Asia Pacific Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
9.1.4. Asia Pacific Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
9.1.5. Asia Pacific Pulmonary Arterial Hypertension Drugs Market by Country (2018-2027 USD Mn)
9.1.5.1. China
9.1.5.1.1. China Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
9.1.5.1.2. China Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
9.1.5.1.3. China Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
9.1.5.2. Japan
9.1.5.2.1. Japan Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
9.1.5.2.2. Japan Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
9.1.5.2.3. Japan Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
9.1.5.3. Rest of Asia Pacific
9.1.5.3.1. Rest of Asia Pacific Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
9.1.5.3.2. Rest of Asia Pacific Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
9.1.5.3.3. Rest of Asia Pacific Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)

 

10. Latin America (LATAM) Pulmonary Arterial Hypertension Drugs Market Analysis and Forecast, 2018 – 2027 (USD Mn)


10.1.1. Overview
10.1.2. Latin America Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
10.1.3. Latin America Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
10.1.4. Latin America Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
10.1.5. Latin America Pulmonary Arterial Hypertension Drugs Market by Country (2018-2027 USD Mn)
10.1.5.1. Brazil
10.1.5.1.1. Brazil Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
10.1.5.1.2. Brazil Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
10.1.5.1.3. Brazil Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
10.1.5.2. Mexico
10.1.5.2.1. Mexico Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
10.1.5.2.2. Mexico Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
10.1.5.2.3. Mexico Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
10.1.5.3. Rest of Latin America
10.1.5.3.1. Rest of Latin America Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
10.1.5.3.2. Rest of Latin America Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
10.1.5.3.3. Rest of Latin America Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)

 

11. Middle East and Africa Pulmonary Arterial Hypertension Drugs Market Analysis and Forecast, 2018 – 2027 (USD Mn)


11.1.1. Overview
11.1.2. MEA Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
11.1.3. MEA Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
11.1.4. MEA Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
11.1.5. Middle East and Africa Pulmonary Arterial Hypertension Drugs Market, by Country (2018-2027 USD Mn)
11.1.5.1. GCC
11.1.5.1.1. GCC Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
11.1.5.1.2. GCC Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
11.1.5.1.3. GCC Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
11.1.5.2. South Africa
11.1.5.2.1. South Africa Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
11.1.5.2.2. South Africa Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
11.1.5.2.3. South Africa Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)
11.1.5.3. Rest of MEA
11.1.5.3.1. Rest of MEA Pulmonary Arterial Hypertension Drugs Market by Drug Class (2018-2027 USD Mn)
11.1.5.3.2. Rest of MEA Pulmonary Arterial Hypertension Drugs Market by Route of Administration (2018-2027 USD Mn)
11.1.5.3.3. Rest of MEA Pulmonary Arterial Hypertension Drugs Market by Distribution Channel (2018-2027 USD Mn)

 

12. Company Profiles


12.1. Johnson & Johnson Services, Inc.
12.1.1. Business Description
12.1.2. Financial Health and Budget Allocation
12.1.3. Product Positions/Portfolio
12.1.4. Recent Development
12.1.5. SWOT Analysis
12.2. United Therapeutics Corporation
12.2.1. Business Description
12.2.2. Financial Health and Budget Allocation
12.2.3. Product Positions/Portfolio
12.2.4. Recent Development
12.2.5. SWOT Analysis
12.3. Pfizer, Inc.
12.3.1. Business Description
12.3.2. Financial Health and Budget Allocation
12.3.3. Product Positions/Portfolio
12.3.4. Recent Development
12.3.5. SWOT Analysis
12.4. Acceleron Pharma, Inc.
12.4.1. Business Description
12.4.2. Financial Health and Budget Allocation
12.4.3. Product Positions/Portfolio
12.4.4. Recent Development
12.4.5. SWOT Analysis
12.5. Gilead Sciences, Inc.
12.5.1. Business Description
12.5.2. Financial Health and Budget Allocation
12.5.3. Product Positions/Portfolio
12.5.4. Recent Development
12.5.5. SWOT Analysis
12.6. Bayer AG
12.6.1. Business Description
12.6.2. Financial Health and Budget Allocation
12.6.3. Product Positions/Portfolio
12.6.4. Recent Development
12.6.5. SWOT Analysis
12.7. GlaxoSmithKline Plc.
12.7.1. Business Description
12.7.2. Financial Health and Budget Allocation
12.7.3. Product Positions/Portfolio
12.7.4. Recent Development
12.7.5. SWOT Analysis
12.8. Arena Pharmaceuticals Inc.
12.8.1. Business Description
12.8.2. Financial Health and Budget Allocation
12.8.3. Product Positions/Portfolio
12.8.4. Recent Development
12.8.5. SWOT Analysis
12.9. Merck KGaA
12.9.1. Business Description
12.9.2. Financial Health and Budget Allocation
12.9.3. Product Positions/Portfolio
12.9.4. Recent Development
12.9.5. SWOT Analysis
12.10. Novartis International AG
12.10.1. Business Description
12.10.2. Financial Health and Budget Allocation
12.10.3. Product Positions/Portfolio
12.10.4. Recent Development
12.10.5. SWOT Analysis
Fill the given form to inquiry before buying for Pulmonary Arterial Hypertension Drugs Market Report

(Additional country analysis and conmapny analysis will be added according to the request, we provide free report customization)
(Report covers the impact of COVID-19 on the market)

Request Report Sample
Inquiry Before Buying
Schedule a Call


Select License Type
$ 3995/- Single User License
$ 5995/- Multi User License
$ 7995/- Corporate License

Paypal Certified Payment
For Any Assitance

Email: sales@researchcorridor.com
Why To Choose Us:
  • Markets in over 100+ countries analyzed granularly
  • 35% of our total client are returning clients
  • 1000+ customers globally
  • 100+ paid data sources mined to bring cutting-edge insights
  • 24x5 availability - we are always there when you need us
  • "Free of Cost Report Customization" is available
  • Request a regional report at Best Price
  • Our expert team will assist you with all research need and customization
  • Our expert research analysts will resolve your every query before and after purchasing the report

Impacts of COVID-19
COVID-19 Impact on the Pulmonary Arterial Hypertension Drugs Market


Our Clients